AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24970876 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine after 3-6 months of cyclophosphamide
Number of subjects: 144
Study 24970876 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide after 12 months
Number of subjects: 144
Study 22382150 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2787
Study 22382150 — intervention group
Group type: COMPARATOR
Intervention: HSV-2
Number of subjects: 2787
Study 22382150 — intervention group
Group type: COMPARATOR
Intervention: GUD
Number of subjects: 2787
Study 20724982 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin (energy corrector antioxidants) included in standard treatment schemes
Number of subjects: 61
Study 18417417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback letters based on the transtheoretical model
Number of subjects: 1044
Study 15947324 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Flex therapy
Number of subjects: 89
Study 15947324 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 89
Study 12577187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (part of the Fracture Intervention Trial)
Number of subjects: 909
Study 12577187 — intervention group
Group type: COMPARATOR
Intervention: Hip fractures
Number of subjects: 909
Study 12577187 — intervention group
Group type: COMPARATOR
Intervention: Lumbar vertebral fractures
Number of subjects: 909
Study 12577187 — intervention group
Group type: COMPARATOR
Intervention: Other fractures (thoracic vertebrae, humerus, distal forearm, ankle, and foot)
Number of subjects: 909
Study 9642851 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition task for safe vs neutral faces in panic patients
Number of subjects: 0
Study 9642851 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition task for critical vs accepting faces in panic patients
Number of subjects: 0
Study 9642851 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 1884726 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone beta-cyclodextrin complex (100 mg)
Number of subjects: 8
Study 1884726 — intervention group
Group type: COMPARATOR
Intervention: Micronised spironolactone powder (100 mg)
Number of subjects: 8
Study 1884726 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone tablets (Aldactone) (100 mg)
Number of subjects: 8
Study 6638605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine therapy
Number of subjects: 6
Study 31621274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement melatonin (ME-group) for two months
Number of subjects: 34
Study 31621274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements melatonin, tryptophan, and vitamin B6 (MET-group) for two months
Number of subjects: 34
Study 31032543 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 74
Study 31032543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 31032543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (Stroop test)
Number of subjects: 74
Study 31032543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (Arithmetic test)
Number of subjects: 74
Study 31032543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental relaxation
Number of subjects: 74
Study 28174138 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft model foods
Number of subjects: 58
Study 26809561 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy program delivered by a local NGO to 22 companies
Number of subjects: 45
Study 26809561 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention for 23 control companies
Number of subjects: 45
Study 26809561 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy program
Number of subjects: 45
Study 25174356 — intervention group
Group type: EXPERIMENTAL
Intervention: THAO-Child Health Program (community based intervention)
Number of subjects: 2249
Study 22280521 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish immigrants needing interpretation when using health services (n = 108, 36.5%)
Number of subjects: 416
Study 22280521 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, non-homeownership, low socioeconomic class, poor access to health services, being ill, poor community integration, and being obese
Number of subjects: 416
Study 22280521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income and poor community integration
Number of subjects: 416
Study 20851232 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel administered in two doses of 0.75 mg given 12 h apart
Number of subjects: 3022
Study 20851232 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel administered in a single dose of 1.5 mg
Number of subjects: 3022
Study 20851232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 3022
Study 17931935 — intervention group
Group type: EXPERIMENTAL
Intervention: Satelec ET 40 ultrasonic tip at power 1
Number of subjects: 30
Study 17931935 — intervention group
Group type: EXPERIMENTAL
Intervention: Satelec ET 40 ultrasonic tip at power 5
Number of subjects: 30
Study 17931935 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR 5 ultrasonic tip at power 1
Number of subjects: 30
Study 17931935 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic vibration without coolant
Number of subjects: 30
Study 15684446 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 89
Study 15684446 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of care (CMC)
Number of subjects: 89
Study 12564822 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly parenting classes and weekly meetings with a social worker
Number of subjects: 60
Study 12564822 — intervention group
Group type: COMPARATOR
Intervention: Weekly parenting classes focusing on learning how to meet the infants' needs
Number of subjects: 60
Study 9830286 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-iodine
Number of subjects: 100
Study 9830286 — intervention group
Group type: COMPARATOR
Intervention: Topical broad-spectrum antibiotics
Number of subjects: 100
Study 7634175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy for cancer drugs; specific dosage and duration not mentioned.
Number of subjects: 0
Study 7634175 — intervention group
Group type: COMPARATOR
Intervention: Chronotherapy scheduling method; specific details not mentioned.
Number of subjects: 0
Study 2285091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine injection at the conclusion of knee arthroscopy
Number of subjects: 0
Study 2285091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 0
Study 7396657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and short-term interpersonal psychotherapy (IPT)
Number of subjects: 81
Study 7396657 — intervention group
Group type: COMPARATOR
Intervention: Short-term interpersonal psychotherapy (IPT)
Number of subjects: 81
Study 7396657 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (tricyclic medication)
Number of subjects: 81
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial postnatal care within 24 hours
Number of subjects: 700
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial postnatal care within 7 days
Number of subjects: 700
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial postnatal care within 14 days
Number of subjects: 700
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education by RECO (Relais Cmunataure)
Number of subjects: 700
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing
Number of subjects: 700
Study 31782629 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria prevention
Number of subjects: 700
Study 27566991 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA bifurcation location
Number of subjects: 989
Study 27566991 — intervention group
Group type: EXPERIMENTAL
Intervention: IEA origin
Number of subjects: 989
Study 27566991 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA access recommendation
Number of subjects: 989
Study 27566991 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of demographics
Number of subjects: 989
Study 27647060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Care
Number of subjects: 1357
Study 27647060 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1357
Study 24656963 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-matching insulin bolus (8.30 U [7.50 U-11.50 U])
Number of subjects: 12
Study 24656963 — intervention group
Group type: COMPARATOR
Intervention: Weight-dependent insulin bolus (0.047 U/kg; 3.45 U [2.95 U-3.75 U])
Number of subjects: 12
Study 22657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium caseinate (Cas, 29 g)
Number of subjects: 13
Study 22657838 — intervention group
Group type: EXPERIMENTAL
Intervention: TG‐treated sodium caseinate (Cas‐TG, 29 g)
Number of subjects: 13
Study 22657838 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (Wh, 30 g)
Number of subjects: 13
Study 19570808 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular pacing (LVP, n=15, pacing duration: 4.3+/‐2.6 years)
Number of subjects: 25
Study 19570808 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (RVP, n=10, pacing duration: 7.9+/‐2.9 years)
Number of subjects: 25
Study 19570808 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy children)
Number of subjects: 25
Study 17501955 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied once daily 3 days per week for 4 weeks
Number of subjects: 259
Study 17501955 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied three times a week for 4 weeks
Number of subjects: 259
Study 14745754 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg bw gadobutrol
Number of subjects: 36
Study 14745754 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg bw gadobutrol
Number of subjects: 36
Study 14745754 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg bw Gd-DTPA
Number of subjects: 36
Study 14745754 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg bw gadobutrol (increased flip angle of 40 degrees)
Number of subjects: 36
Study 14745754 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mmol/kg bw Gd-DTPA (in volunteers)
Number of subjects: 36
Study 11431614 — intervention group
Group type: EXPERIMENTAL
Intervention: Migav‐Ladach method (ML)
Number of subjects: 0
Study 11431614 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel technique
Number of subjects: 0
Study 9699780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or prophylactic interventions in childhood asthma
Number of subjects: 0
Study 9699780 — intervention group
Group type: COMPARATOR
Intervention: Randomization of individuals
Number of subjects: 0
Study 9699780 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures of outcome (lung function)
Number of subjects: 0
Study 8050544 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperreactivity defined as PD20 ≤ 12.25 mumol
Number of subjects: 2415
Study 8050544 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 2415
Study 8050544 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 2415
Study 8050544 — intervention group
Group type: COMPARATOR
Intervention: Atopy (measured by skin wheal response)
Number of subjects: 2415
Study 8050544 — intervention group
Group type: COMPARATOR
Intervention: Older age groups (60-70 years)
Number of subjects: 2415
Study 8050544 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute FEV1
Number of subjects: 2415
Study 8050544 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 % predicted
Number of subjects: 2415
Study 8050544 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 % FVC
Number of subjects: 2415
Study 2378705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafresh (Faulding)
Number of subjects: 40
Study 2378705 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 342217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg q.i.d.
Number of subjects: 71
Study 342217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30193971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy
Number of subjects: 122
Study 30193971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cyst deroofing
Number of subjects: 122
Study 24621459 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training program
Number of subjects: 85
Study 24621459 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 85
Study 26542495 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 1035
Study 23916874 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-µm PVA particles (group A)
Number of subjects: 80
Study 23916874 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-µm PVA particles (group B)
Number of subjects: 80
Study 21856483 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 910
Study 21856483 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 910
Study 19188327 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization (angioplasty-first approach), n = 76
Number of subjects: 151
Study 19188327 — intervention group
Group type: COMPARATOR
Intervention: Supervised hospital-based exercise, n = 75
Number of subjects: 151
Study 19188327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Endovascular revascularization and Supervised exercise)
Number of subjects: 151
Study 16898305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT) VBM
Number of subjects: 40
Study 16898305 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 40
Study 14722167 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 micro g kg(‐1) min(‐1)
Number of subjects: 49
Study 14722167 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.0 micro g kg(‐1) min(‐1) and greater
Number of subjects: 49
Study 14722167 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 12014765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical injection of 301U oxytocin in 27mls saline
Number of subjects: 35
Study 12014765 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo) 30mls
Number of subjects: 35
Study 9783759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iloprost 50 microg
Number of subjects: 103
Study 9783759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iloprost 100 microg
Number of subjects: 103
Study 9783759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 7869062 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls in patients with a history of falling
Number of subjects: 82
Study 7869062 — intervention group
Group type: COMPARATOR
Intervention: Patients with no history of falling (Control)
Number of subjects: 82
Study 7869062 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls associated with injuries
Number of subjects: 82
Study 7869062 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls frequency
Number of subjects: 82
Study 7869062 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for falling
Number of subjects: 82
Study 2494024 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal support program
Number of subjects: 94
Study 2494024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 5507464 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the calf muscles
Number of subjects: 110
Study 5507464 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated legs (control)
Number of subjects: 110
Study 31257996 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral approach (TFA)
Number of subjects: 101
Study 31257996 — intervention group
Group type: COMPARATOR
Intervention: Transradial approach (TRA)
Number of subjects: 101
Study 28990173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg/m2 every 2 weeks (for males)
Number of subjects: 268
Study 28990173 — intervention group
Group type: COMPARATOR
Intervention: Rituximab 375 mg/m2 (for females)
Number of subjects: 268
Study 28990173 — intervention group
Group type: COMPARATOR
Intervention: Standard rituximab schedule
Number of subjects: 268
Study 28990173 — intervention group
Group type: COMPARATOR
Intervention: Upfront dose-dense rituximab schedule
Number of subjects: 268
Study 27128218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0
Study 27128218 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6280 10 mg
Number of subjects: 0
Study 27128218 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6280 40 mg
Number of subjects: 0
Study 27128218 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7325 2 mg
Number of subjects: 0
Study 27128218 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7325 10 mg
Number of subjects: 0
Study 27128218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23979737 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 50 mg in fed state
Number of subjects: 48
Study 23979737 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 200 mg in fed state
Number of subjects: 48
Study 23979737 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-824 1000 mg in fed state
Number of subjects: 48
Study 23979737 — intervention group
Group type: COMPARATOR
Intervention: PA-824 50 mg in fasted state
Number of subjects: 48
Study 23979737 — intervention group
Group type: COMPARATOR
Intervention: PA-824 200 mg in fasted state
Number of subjects: 48
Study 23979737 — intervention group
Group type: COMPARATOR
Intervention: PA-824 1000 mg in fasted state
Number of subjects: 48
Study 21331567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ZOL 5 mg yearly
Number of subjects: 2127
Study 21331567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 19844108 — intervention group
Group type: EXPERIMENTAL
Intervention: Geranylgeranylacetone (GGA) 300 mg/day
Number of subjects: 10
Study 19844108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17946174 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telehealth program
Number of subjects: 0
Study 17946174 — intervention group
Group type: EXPERIMENTAL
Intervention: VALUE program technology
Number of subjects: 0
Study 15530193 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (10 mg/kg orally or through a gastric tube)
Number of subjects: 43
Study 15530193 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (10 mg/kg orally or through a gastric tube)
Number of subjects: 43
Study 15530193 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 43
Study 15530193 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 43
Study 11354864 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS total knee replacement without resurfacing of the patella
Number of subjects: 436
Study 9024026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS) 10 micrograms diluted in 1, 2, or 3 mL of normal saline
Number of subjects: 45
Study 9024026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS)
Number of subjects: 45
Study 8515849 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 8515849 — intervention group
Group type: COMPARATOR
Intervention: Propofol+fentanyl
Number of subjects: 0
Study 8515849 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 0
Study 8515849 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesia inadequacy
Number of subjects: 0
Study 2871744 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 269
Study 2871744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 31647564 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text‐delivered scheduled gradual reduction (SGR) program plus support texts
Number of subjects: 314
Study 31647564 — intervention group
Group type: COMPARATOR
Intervention: SMS support messages alone
Number of subjects: 314
Study 28830693 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (ZV) and quadrivalent inactivated influenza vaccine (IIV4) administered concomitantly
Number of subjects: 882
Study 28830693 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent inactivated influenza vaccine (IIV4) administered sequentially
Number of subjects: 882
Study 27143689 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel treatment with SNP analysis
Number of subjects: 623
Study 27143689 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC14 SNP (rs875858)
Number of subjects: 623
Study 27143689 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA knockdown of VAC14 in stem cell-derived peripheral neuronal cells
Number of subjects: 623
Study 27143689 — intervention group
Group type: COMPARATOR
Intervention: VAC14 heterozygous mice
Number of subjects: 623
Study 24144627 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (7‐36) amide infusion (1.5 pmol/kg/min)
Number of subjects: 77
Study 24144627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22606064 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera cream (n = 32), applied 3 times a day for 10 days
Number of subjects: 66
Study 22606064 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendula officinalis ointment (n = 34), applied 3 times a day for 10 days
Number of subjects: 66
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 64
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling calls
Number of subjects: 64
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Print materials
Number of subjects: 64
Study 20605073 — intervention group
Group type: EXPERIMENTAL
Intervention: Helpful materials
Number of subjects: 64